Disease modification in osteoarthritis: are we there yet?
A disease-modifying osteoarthritis drug (DMOAD) is a drug that modifies the underlying OA pathophysiology and potentially inhibits the structural damage to prevent or reduce long-term disability with potential symptomatic relief. The focus of this narrative review is on describing the state of the field for disease-modifying pharmacologic agents that are in late-stage development-specifically phase 2/3.